Shaily Engineering Plastics Limited has informed the Exchange about Investor Presentation
SHAILY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shaily Engineering Plastics reported a strong Q1FY26 (quarter ended 30 June 2025) with consolidated revenue rising 38% YoY to Rs. 246.7 Cr, driven mainly by the Healthcare segment which surged 181% YoY to Rs. 77.2 Cr on rising demand for GLP-1 drug delivery devices. EBITDA jumped 95% YoY to Rs. 70.4 Cr with margins expanding 840 basis points to 28.5%, while Profit After Tax more than doubled (up 136%) to Rs. 41.1 Cr. Standalone performance was even sharper, with PAT up 268% to Rs. 36.0 Cr. Capital efficiency improved sharply with RoCE rising to 40.5% (from 24.4%) and RoE at 30.8%. The company highlighted new contracts for GLP-1 pen supply, FMCG male accessories, and ongoing installation of 19 injection moulding machines to meet rising healthcare demand, while CARE upgraded its long-term credit rating to A+ (Stable).
Strong across-the-board beat on revenue, margins, and profitability signals robust business momentum, particularly in the high-growth healthcare/GLP-1 segment, which should be viewed positively by shareholders; however, the Total Debt/Equity ratio rose to 2.1 from 1.7, worth monitoring despite the rating upgrade.